Диссертация (1154734), страница 16
Текст из файла (страница 16)
P. 107-114.105. Takai T. Roles of Fc receptors in autoimmunity // Nat Rev Immunol. 2002. Vol.2, № 8. P. 580-592.106. Vassilopoulos D., Z.M. Younossi, E. Hadziyannis, et al. Study of host andvirological factors of patients with chronic HCV infection and associatedlaboratory or clinical autoimmune manifestations // Clin Exp Rheumatol. 2003.Vol. 21, № 6, Suppl 32. P. 101-111.107. Fabris M., L. Quartuccio, S. Salvin, et al. Fibronectin gene polymorphisms areassociated with the development of B-cell lymphoma in type II mixedcryoglobulinemia // Ann Rheum Dis.
2008. Vol. 67, № 1. P. 80-83.108. Fornasieri A., S. Armelloni, P. Bernasconi, et al. High binding ofimmunoglobulin M kappa rheumatoid factor from type II cryoglobulins tocellular fibronectin: a mechanism for induction of in situ immune complexglomerulonephritis? // Am J Kidney Dis. 1996. Vol. 27, № 4. P. 476-483.109. Avila J.J., P.A. Lympany, P. Pantelidis, et al. Fibronectin gene polymorphismsassociated with fibrosing alveolitis in systemic sclerosis // Am J Respir Cell MolBiol.
1999. Vol. 20, №1. P. 106-112.110. Yang H.Y., S.L. Su, Y.J. Peng, et al. An intron polymorphism of the fibronectingene is associated with end-stage knee osteoarthritis in a Han Chinese population:two independent case-control studies // BMC Musculoskelet Disord. 2014. Vol.15, P. 173.111. Старостина Е.Е. Клиническое значение полиморфизма генов гемостаза итромбоцитарных рецепторов у больных хроническим гепатитом С //102автореферат дис. ... кандидата медицинских наук: 14.01.04. // СтаростинаЕкатерина Евгеньевна.
Москва. 2016.112. Pietrogrande M., S. De Vita, A.L. Zignego, et al. Recommendations for themanagement of mixed cryoglobulinemia syndrome in hepatitis C virus-infectedpatients // Autoimmun Rev. 2011. Vol. 10, № 8. P. 444-454.113. Gragnani L., E. Fognani, A. Piluso, et al. Long-term effect of HCV eradication inpatients with mixed cryoglobulinemia: a prospective, controlled, open-label,cohort study // Hepatology. 2015. Vol. 61, № 4. P.
1145-1153.114. Т.М. И. Лечение внепеченочных проявлений хронической HCV-инфекции //Сучасна гастроентерологiя. 2006. Vol. 3, № 29. P. 46-55.115. ЧерноваО.А..Факторы,влияющиенаэффективностьлечениявнепеченочных поражений, ассоциированных с HCV-криоглобулинемией //автореферат дис. ... кандидата медицинских наук: 14.01.04. // Чернова ОльгаАлександровна. Москва. 2016.116.
Gota C.,L. Calabrese. Induction of clinical autoimmune disease by therapeuticinterferon-alpha // Autoimmunity. 2003. Vol. 36, № 8. P. 511-518.117. Boonyapisit K.,B. Katirji. Severe exacerbation of hepatitis C-associated vasculiticneuropathy following treatment with interferon alpha: a case report and literaturereview // Muscle Nerve. 2002. Vol. 25, № 6.
P. 909-913.118. Wink F., P.M. Houtman,T.L. Jansen. Rituximab in cryoglobulinaemic vasculitis,evidence for its effectivity: a case report and review of literature // ClinRheumatol. 2011. Vol. 30, № 2. P. 293-300.119. Cacoub P., A. Delluc, D. Saadoun, et al. Anti-CD20 monoclonal antibody(rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? // AnnRheum Dis. 2008. Vol. 67, № 3. P. 283-287.120. Saadoun D., M. Resche Rigon, S. Pol, et al. PegIFNalpha/ribavirin/proteaseinhibitorcombinationinseverehepatitisCvirus-associatedcryoglobulinemia vasculitis // J Hepatol.
2015. Vol. 62, № 1. P. 24-30.mixed103121. Werner C.R., J.M. Schwarz, D.P. Egetemeyr, et al. Second-generation directacting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors ofSVR12 // World J Gastroenterol. 2016. Vol. 22, № 35. P. 8050-8059.122. Gragnani L., M. Visentini, E. Fognani, et al. Prospective study of guidelinetailored therapy with direct-acting antivirals for hepatitis C virus-associatedmixed cryoglobulinemia // Hepatology. 2016. Vol.
64, № 5. P. 1473-1482.123. Saadoun D., V. Thibault, S.N. Si Ahmed, et al. Sofosbuvir plus ribavirin forhepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDICstudy // Ann Rheum Dis. 2016. Vol. 75, № 10. P. 1777-1782.124. Mukhtyar C., R. Lee, D. Brown, et al. Modification and validation of theBirmingham Vasculitis Activity Score (version 3) // Ann Rheum Dis. 2009. Vol.68, № 12.
P. 1827-1832.125. Моисеев С.В. АНЦА-ассоциированные васкулиты: спорные вопросыклассификации, диагностики и оценки активности и современные подходык лечению // Клиническая фармакология и терапия. 2014. Vol. 23, № 1. P. 4450.126. Woo J.G., G. Sun, M. Haverbusch, et al. Quality assessment of buccal versusblood genomic DNA using the Affymetrix 500 K GeneChip // BMC Genet. 2007.Vol. 8, P.
79.127. Abraham J.E., M.J. Maranian, I. Spiteri, et al. Saliva samples are a viablealternative to blood samples as a source of DNA for high throughput genotyping// BMC Med Genomics. 2012. Vol. 5, P. 19.128. Bulik-Sullivan B.K., P.R. Loh, H.K. Finucane, et al. LD Score regressiondistinguishes confounding from polygenicity in genome-wide association studies// Nat Genet. 2015. Vol. 47, № 3. P. 291-295.129. Purcell S.M., N.R. Wray, J.L. Stone, et al.
Common polygenic variationcontributes to risk of schizophrenia and bipolar disorder // Nature. 2009. Vol.460, № 7256. P. 748-752.104130. Чуланов В., Пименов Н., Мамонова Н. и др. Хронический гепатит С какпроблема здравоохранения России: сегодня и завтра // Терапевтическийархив. 2015. Том 87, № 11. С. 5-10.131. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing,and treating adults infected with hepatitis C virus // Hepatology. 2015. Vol.
62,№ 3. P. 932-954.132. James A.C., J.O. Szot, K. Iyer, et al. Notch4 reveals a novel mechanismregulating Notch signal transduction // Biochim Biophys Acta. 2014. Vol 1843,№7. P. 1272-1284.133. De Re V., L. Caggiari, G. Monti, et al. HLA DR-DQ combination associated withthe increased risk of developing human HCV positive non-Hodgkin's lymphomais related to the type II mixed cryoglobulinemia // Tissue Antigens. 2010. Vol. 75,№ 2. P. 127-135.134. Reyes-Aviles E., L. Kostadinova, A. Rusterholtz, et al. Presence of RheumatoidFactor during Chronic HCV Infection Is Associated with Expansion of MatureActivated Memory B-Cells that Are Hypo-Responsive to B-Cell ReceptorStimulation and Persist during the Early Stage of IFN Free Therapy // PLoS One.2015.
Vol. 10, № 12. P. e0144629..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
